Protara Therapeutics, Inc.

NASDAQ:TARA

Biotechnology

Healthcare
$2.34 -1.27%

-$0.05 today

Market cap
$144.07M
Beta
1.45
P/E (TTM)
-2.7
EPS (TTM)
-$1.48
52W Low $2.77High $7.82

Volume 1.15M

Average 0.73M

TARA Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Protara Therapeutics, Inc.NASDAQ: TARA

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares of 42.84M shares rose 5.2% year over year, behind the +56.7% change in trailing-twelve-month weighted avg shares. Sequentially, it fell 7.0% from the prior quarter. Over 3 fiscal years it compounded at +56.1% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +5.2% toward the trailing-twelve-month pace of +56.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
42.84M-7.0% QoQ
Last fiscal yearDec 2025
42.84M+108.0% YoY
LTMMar 2026
43.36M+56.7% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+5.2%——
1 year+108.0%——
3-year CAGR+56.1%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
42.84M USD
Year-over-year change
+108.0%
4-year CAGR
+39.7%

Weighted Avg Shares vs competitors

How TARA compares with its peers on the latest reported figures

  • TARA's LTM Mar 2026 weighted avg shares of 43.36M shares is the 7th highest of the 10 companies compared; the peer median is 89.2M shares.
  • Its year-over-year change of +56.7% is the 3rd highest of 9, against a peer median of +16.3%.
  • Over three fiscal years its annual growth of +56.1% compares with a peer median of +17.1%.
TARA Competitors Peer median
Weighted Avg Shares for TARA and competitors
Company Period LTM YoY 3-year CAGR
SGMOSangamo Therapeutics, Inc.LTM Mar 2026322.14M +52.9%+22.0%
IVVDInvivyd, Inc.LTM Mar 2026193.02M +61.8%+16.7%
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026179.3M +96.8%+77.8%
OABIOmniAb, Inc.LTM Mar 2026119.25M +15.1%+10.0%
CDXSCodexis, Inc.LTM Mar 202689.2M +16.6%+10.1%
PRLDPrelude Therapeutics IncorporatedLTM Mar 202674.4M -1.9%+17.6%
TARAProtara Therapeutics, Inc.LTM Mar 202643.36M +56.7%+56.1%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 202638.39M +2.6%+14.7%
NTHINeonc Technologies Holdings, Inc.LTM Mar 202620.19M ——
MDWDMediWound Ltd.LTM Mar 202611.89M +16.1%+31.6%
Peer median (excluding TARA) 89.2M+16.3%+17.1%

Competitors are the stored peer set for TARA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00341K0362K
Gross Profit00(341K)0(362K)
Gross Margin—————
Research & Development21.09M16.81M24.79M31.7M42.63M
Selling, General & Admin26.4M20.74M18.62M17.45M21.92M
Operating Expenses47.49M67.06M43.27M49.15M64.19M
Depreciation & Amortization117K248K341K332K362K
EBITDA(45.4M)(64.57M)(40.08M)(44.26M)(57.08M)
EBITDA Margin—————
Operating Income(47.49M)(67.06M)(43.61M)(49.15M)(64.55M)
Operating Margin—————
Interest Income237K1.11M2.73M4.14M6.33M
Interest Expense1.74M1.14M000
Other Income / Expenses237K1.11M3.19M4.56M7.11M
Income Before Tax(47.25M)(65.95M)(40.42M)(44.6M)(57.44M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(47.25M)(65.95M)(40.42M)(44.6M)(57.44M)
Net Margin—————
EPS (Basic)(4.20)(5.86)(3.57)(2.17)(1.34)
EPS (Diluted)(4.20)(5.86)(3.57)(2.17)(1.34)
Weighted Avg Shares11.23M11.26M11.33M20.59M42.84M
Weighted Avg Shares (Diluted)11.23M11.26M11.33M20.59M42.84M

Protara Therapeutics, Inc.

NASDAQ:TARA

Intrinsic Alpha fair value

Locked

Current Price

$2.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.